Crosstalk between Macrophages and Myxoid Liposarcoma Cells Increases Spreading and Invasiveness of Tumor Cells.

myxoid liposarcoma tumor associated macrophages tumor microenvironment tumor-infiltrating lymphocytes

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
30 Jun 2021
Historique:
received: 11 06 2021
revised: 24 06 2021
accepted: 26 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

Myxoid liposarcoma (MLPS) is the second most common subtype of liposarcoma and has tendency to metastasize to soft tissues. To date, the mechanisms of invasion and metastasis of MLPS remain unclear, and new therapeutic strategies that improve patients' outcomes are expected. In this study, we analyzed by immunohistochemistry the immune cellular components and microvessel density in tumor tissues from patients affected by MLPS. In order to evaluate the effects of primary human MLPS cells on macrophage polarization and, in turn, the ability of macrophages to influence invasiveness of MLPS cells, non-contact and 3D organotypic co-cultures were set up. High grade MLPS tissues were found heavily vascularized, exhibited a CD3, CD4, and CD8 positive T lymphocyte-poor phenotype and were massively infiltrated by CD163 positive M2-like macrophages. Conversely, low grade MLPS tissues were infiltrated by a discrete amount of CD3, CD4, and CD8 positive T lymphocytes and a scarce amount of CD163 positive macrophages. Kaplan-Meier analysis revealed a shorter Progression Free Survival in MLPS patients whose tumor tissues were highly vascularized and heavily infiltrated by CD163 positive macrophages, indicating a clear-cut link between M2-like macrophage abundance and poor prognosis in patients. Moreover, we documented that, in co-culture, soluble factors produced by primary human MLPS cells induce macrophage polarization toward an M2-like phenotype which, in turn, increases MLPS cell capability to spread into extracellular matrix and to cross endothelial monolayers. The identification of M2-like polarization factors secreted by MLPS cells may allow to develop novel targeted therapies counteracting MLPS progression.

Identifiants

pubmed: 34209309
pii: cancers13133298
doi: 10.3390/cancers13133298
pmc: PMC8268435
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Mod Pathol. 2013 Feb;26(2):282-8
pubmed: 22936067
Br J Cancer. 2015 Feb 3;112(3):547-55
pubmed: 25562433
Curr Opin Oncol. 2013 Jul;25(4):379-83
pubmed: 23673410
Front Oncol. 2020 Apr 15;10:489
pubmed: 32351889
Br J Pharmacol. 2021 May;178(9):1955-1972
pubmed: 31975481
Cancer Immunol Res. 2017 Jul;5(7):547-559
pubmed: 28515123
J Leukoc Biol. 2006 Oct;80(4):705-13
pubmed: 16864600
Am J Surg Pathol. 2021 Jan;45(1):e1-e23
pubmed: 32796172
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Mol Cancer Ther. 2019 Apr;18(4):834-844
pubmed: 30787173
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4760-5
pubmed: 10781081
Cancer Res. 2010 Mar 15;70(6):2235-44
pubmed: 20215499
Cells. 2020 Apr 24;9(4):
pubmed: 32344648
Clin Cancer Res. 2013 Jul 1;19(13):3404-15
pubmed: 23653148
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Sarcoma. 2011;2011:538085
pubmed: 22190864
Cancer. 2012 Sep 15;118(18):4564-70
pubmed: 22359263
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Hum Pathol. 2009 Sep;40(9):1244-51
pubmed: 19368956
Orthop Traumatol Surg Res. 2015 Feb;101(1):103-7
pubmed: 25583234
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
J Exp Clin Cancer Res. 2017 Dec 08;36(1):180
pubmed: 29216889
Mod Pathol. 2019 Dec;32(12):1772-1785
pubmed: 31263176
Ann Surg Oncol. 2007 Apr;14(4):1507-14
pubmed: 17252290
Sci Rep. 2017 May 2;7(1):1312
pubmed: 28465589
Cancer. 2017 Sep 1;123(17):3291-3304
pubmed: 28463396
Clin Cancer Res. 2020 Nov 15;26(22):5801-5808
pubmed: 32601077
Sci Rep. 2019 Aug 21;9(1):12169
pubmed: 31434916
Immunol Rev. 2008 Apr;222:155-61
pubmed: 18364000
Clin Cancer Res. 2001 Dec;7(12):3977-87
pubmed: 11751490
Sarcoma. 2011;2011:842842
pubmed: 21253510
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32792357
Sarcoma. 2020 Mar 31;2020:6716742
pubmed: 32317857
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2491-6
pubmed: 22308361
Cancer. 2007 Jun 15;109(12):2522-31
pubmed: 17510918
Nat Rev Immunol. 2015 Feb;15(2):73-86
pubmed: 25614318
Cell Mol Immunol. 2020 Aug;17(8):807-821
pubmed: 32612154
Front Biosci. 2008 Jan 01;13:453-61
pubmed: 17981560
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Sarcoma. 2012;2012:345161
pubmed: 22550416
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
Front Immunol. 2019 Aug 20;10:1875
pubmed: 31481956
Cancers (Basel). 2021 Mar 03;13(5):
pubmed: 33802565
J Oncol Pract. 2016 Mar;12(3):221-7
pubmed: 26962163
Clin Cancer Res. 2010 Jul 15;16(14):3581-93
pubmed: 20522586
Oncoimmunology. 2016 Dec 7;6(2):e1265716
pubmed: 28344871
Oncogene. 2000 Dec 7;19(52):6015-22
pubmed: 11146553
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Cancer Res. 2007 Oct 1;67(19):9518-27
pubmed: 17909062
Cancer Metastasis Rev. 2006 Sep;25(3):315-22
pubmed: 16967326
J Exp Clin Cancer Res. 2014 Apr 11;33:33
pubmed: 24726063
Curr Oncol. 2020 Feb;27(Suppl 1):17-23
pubmed: 32174754
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
Front Immunol. 2014 Oct 17;5:514
pubmed: 25368618
FEBS J. 2006 Feb;273(4):732-45
pubmed: 16441660
Nature. 2012 Jan 18;481(7381):306-13
pubmed: 22258609
Front Immunol. 2014 Mar 26;5:127
pubmed: 24723924
Nature. 2016 Dec 22;540(7634):588-592
pubmed: 27974798

Auteurs

Michele Minopoli (M)

Neoplastic Progression Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.

Sabrina Sarno (S)

Neoplastic Progression Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.

Lucia Cannella (L)

Medical Oncology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.

Salvatore Tafuto (S)

Medical Oncology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.

Gosuè Scognamiglio (G)

Pathology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.

Michele Gallo (M)

Musculoskeletal Surgery Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.

Flavio Fazioli (F)

Musculoskeletal Surgery Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.

Rosa Azzaro (R)

Transfusion Medicine Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.

Gaetano Apice (G)

Medical Oncology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.

Biagio De Angelis (B)

Department of Onco-Haematology and Cell and Gene Therapy Unit, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.

Elena Tamborini (E)

Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Cecilia Garofalo (C)

Advanced Translational Research Laboratory, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

Ymera Pignochino (Y)

Department of Clinical and Biological Sciences, University of Turin, 10124 Torino, Italy.
Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.

Laura Mercatali (L)

Osteoncology and Rare Tumors Center, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) IRCCS, 47010 Meldola, Italy.

Toni Ibrahim (T)

Osteoncology and Rare Tumors Center, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) IRCCS, 47010 Meldola, Italy.

Rita Falcioni (R)

Department of Research, Diagnosis and Innovative Technology, IRCCS Regina Elena National Cancer Institute, 00128 Rome, Italy.

Beatrice Valenti (B)

Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, 33081 Aviano, Italy.

Roberta Maestro (R)

Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, 33081 Aviano, Italy.

Katia Scotlandi (K)

Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.

Annarosaria De Chiara (A)

Pathology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.

Maria Vincenza Carriero (MV)

Neoplastic Progression Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', 80131 Naples, Italy.

Classifications MeSH